Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Go To Specialties
MassGeneral Hospital for Children
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Sweetser completed his MD/PhD at Wash. Univ Sch of Med in St. Louis, and Pediatric Residency training at St. Louis Children's Hosp. He did his Medical Genetics Fellowship training at the Wash. Univ Sch of Med in St. Louis and the Univ of Wash in Seattle along with a Biochemical Genetics Fellowship. He subsequently completed a Fellowship in Pediatric Hematology/Oncology at the Univ of Wash. in Seattle. Since 2003 Dr. Sweetser has been at Massachusetts General Hospital seeing patients in Ped. Hem/Onc as well as Medical Genetics and Metabolism and runs a research lab in leukemia and medical genetics. Dr. Sweetser is Chief of the Division of Medical Genetics and Metabolism. Under his leadership the Genetics Program has markedly expanded more than doubling the number of patient visits with new specialty clinics in Turner Syndrome, Hereditary Hemorrhagic Telangiectasia, CHARGE syndrome, a multidisciplinary Sensorineural Hearing Loss Clinic at the MEEI, an Autism Genetics Clinic at the Lurie Center, Pitt Hopkins Syndrome, Pediatric Cancer Predisposition Clinic, as well as a world renown Down Syndrome clinic. Dr. Sweetser has been a leader in the application of whole exome sequencing to clinical diagnostics. Dr. Sweetser is the MGH site director for the NIH sponsored Undiagnosed Diseases Network linking 11 medical centers around the country to accelerate discovery and innovation in the way we diagnose and treat patients with previously undiagnosed diseases.
View my most recent research
The Sweetser laboratory investigates how leukemia and other cancers develop with the goal of developing novel, safer, and more effective therapies. We are investigating how the Groucho/TLE family of co-repressors function as potent tumor suppressors of acute myeloid leukemia and their roles in normal development and cell function. Knock-out mice for Tle1 and Tle4 have identified critical roles for these proteins in hematopoiesis, bone, lung, and brain development, as well as a critical role in limiting inflammation. We have defined critical inflammatory signaling pathways mediating cell proliferation and synergistic cross talk within the cancer niche. The laboratory is also using whole exome sequencing to characterize underlying cancer predisposition genes in patients with a variety of pediatric malignancies. As the MGH site director for the newly established HMS Undiagnosed Diseases Center and Chief of Medical Genetics and Metabolism at MGH, Dr. Sweetser is also leading a group of clinicians and researchers actively engaged in elucidating the underlying basis of a wide variety of human diseases.
View my most recent publications at PubMed
Sofia is one of an estimated 500 children in the world diagnosed with Pitt Hopkins syndrome, a genetic disorder that affects development, speech and intellect. This little girl, although tiny in size, is proving she is capable of big things despite her rare diagnosis.
The Pitt Hopkins Syndrome Clinic will work with patients and families to further understand, diagnose, and treat Pitt Hopkins Syndrome, a rare genetic disorder.
MassGeneral Hospital for Children will soon open the world’s first Pitt Hopkins Syndrome Clinic. Made possible by a generous donation from parents of two young women with Pitt Hopkins Syndrome, the clinic will focus on providing knowledge-based medical care and serving the comprehensive medical needs of individuals with the disease.
David Sweetser, MD, PhD, explains why he is running for the MassGeneral Marathon Team Fighting Kids’ Cancer . . . One Step at a Time.
David Sweetser, MD, PhD, chief of the Medical Genetics Program at MassGeneral Hospital for Children, explains why it is such an opportune time to be in the field.
MGH Hotline 9.17.10 September is National Childhood Cancer Awareness Month.
Back to Top